When should IV dextrose‑normal saline (D5NS) be administered to a pregnant patient with persistent nausea and vomiting, and what is the recommended dosing and monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IV Dextrose-Normal Saline in Pregnancy-Related Nausea and Vomiting

Do not use IV dextrose-normal saline (D5NS) for pregnant patients with nausea and vomiting—instead, use normal saline (0.9% NaCl) with added potassium chloride as the appropriate intravenous hydration. 1

Recommended IV Fluid Regimen

The 2024 RCOG Green-top Guideline explicitly states that normal saline (0.9% NaCl) with additional potassium chloride in each bag is the most appropriate intravenous hydration for pregnant women with hyperemesis gravidarum (HG) and severe nausea/vomiting of pregnancy (NVP). 1 This is a Grade C recommendation based on current evidence.

Administration Protocol:

  • Fluid type: 0.9% normal saline
  • Additives: Potassium chloride added to each bag
  • Monitoring: Daily electrolyte monitoring to guide potassium supplementation
  • Rate: Guided by clinical assessment of dehydration severity

Critical Thiamine Supplementation

Before administering any dextrose-containing fluids or parenteral nutrition, thiamine must be given to prevent Wernicke's encephalopathy—a potentially fatal complication. 1

  • Oral thiamine: 100 mg three times daily, OR
  • IV thiamine: As part of vitamin B complex (Pabrinex®)
  • Timing: Give to all women admitted with vomiting or severely reduced dietary intake, especially before dextrose administration

This is critical because thiamine deficiency in HG can cause Wernicke's encephalopathy with fetal loss in 50% and maternal death in 5% of cases. 1

Why Not Dextrose-Containing Solutions?

The evidence comparing D5NS versus normal saline shows no clinically meaningful advantage for dextrose-containing solutions:

A 2013 randomized controlled trial directly compared 5% dextrose-0.9% saline against 0.9% saline alone in 202 women with HG. 2 The study found:

  • No difference in resolution of ketonuria (9.9% vs 10.9%, p=0.99)
  • No difference in well-being scores at 24 hours
  • Minimal difference in nausea scores that dissipated by 24 hours
  • No difference in vomiting, electrolyte correction, length of hospitalization, or duration of IV therapy

The guideline explicitly states that ketonuria should not be used to inform clinical decision-making about treatments or hydration status, as it is not an indicator of dehydration in pregnancy. 1 This removes the traditional rationale for using dextrose solutions.

When to Initiate IV Fluids

Start IV hydration when patients demonstrate:

  • Persistent vomiting preventing oral intake
  • Signs of dehydration: tachycardia, postural hypotension, reduced skin turgor, dry mucous membranes
  • Inability to tolerate oral antiemetics
  • Electrolyte abnormalities: hyponatremia, hypokalaemia, metabolic hypochloraemic alkalosis

Do not rely on ketonuria to determine need for IV fluids—it is not associated with HG severity. 1

Complete Management Algorithm

1. Assessment

  • Use PUQE score for mild-moderate NVP or HELP score for severe NVP/HG to objectively assess severity 1
  • Check electrolytes (sodium, potassium, chloride), renal function, and consider thyroid function tests
  • Assess for signs of dehydration (not ketonuria)

2. Antiemetic Therapy (concurrent with IV fluids)

  • First-line: Antihistamines, phenothiazines, or doxylamine/pyridoxine 1
  • Second-line: Ondansetron or metoclopramide (give metoclopramide IV slowly over ≥3 minutes to minimize extrapyramidal effects) 1
  • Combination therapy if single agents fail

3. IV Fluid Administration

  • Normal saline 0.9% with potassium chloride
  • Monitor electrolytes daily and adjust potassium accordingly
  • Give thiamine before any dextrose administration

4. Discharge Criteria

Patients should only be discharged when: 1

  • Appropriate antiemetic therapy has been tolerated
  • Adequate oral nutrition and hydration tolerated
  • Concurrent conditions managed
  • Clear plan for continued antiemetics and access to further care

Common Pitfalls to Avoid

  1. Using ketonuria to guide treatment decisions—it does not correlate with dehydration or severity 1

  2. Forgetting thiamine supplementation—this can lead to catastrophic Wernicke's encephalopathy, particularly when giving dextrose 1

  3. Discontinuing antiemetics too early—almost one-third of women are readmitted; continued antiemetic therapy reduces readmission risk 1

  4. Rapid IV metoclopramide administration—always give over ≥3 minutes to minimize extrapyramidal side effects 1

  5. Using iron supplements during acute phase—two-thirds of women report improvement in NVP severity after discontinuing iron 1

Special Considerations

Thromboprophylaxis: Women with HG have 4.4 times increased risk of DVT while persistently vomiting, but prophylaxis can be discontinued at discharge or when HG resolves. 1

Fetal monitoring: Women with severe NVP/HG continuing into late second or third trimester should receive serial growth scans, as low pregnancy weight gain (<7 kg) increases risk of preterm birth and low birth weight. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.